These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17513826)

  • 1. PACS 01 trial: questions about patients' characteristics and reported results.
    Demonty G; Bogaerts J
    J Clin Oncol; 2007 May; 25(15):2143; author reply 2143-4. PubMed ID: 17513826
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.
    Ferretti G; Felici A; Carlini P; Cognetti F
    J Natl Cancer Inst; 2007 Sep; 99(18):1416. PubMed ID: 17848675
    [No Abstract]   [Full Text] [Related]  

  • 3. [The evaluation of therapeutic results as exemplified by the adjuvant chemotherapy of breast carcinoma].
    von Heyden HW
    Dtsch Med Wochenschr; 2000 Mar; 125(11):340. PubMed ID: 10761479
    [No Abstract]   [Full Text] [Related]  

  • 4. Metformin as an addition to conventional chemotherapy in breast cancer.
    Grenader T; Goldberg A; Shavit L
    J Clin Oncol; 2009 Dec; 27(35):e259; author reply e260. PubMed ID: 19884518
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the hormonal treatment of breast cancer.
    Boughey JC; Buzdar AU; Hunt KK
    Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.
    Julian-Reynier C; Genève J; Dalenc F; Genre D; Monnier A; Kerbrat P; Largillier R; Serin D; Rios M; Roché H; Jimenez M; Tarpin C; Maraninchi D;
    J Clin Oncol; 2007 Jul; 25(21):3038-44. PubMed ID: 17536083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach.
    Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba PF; Chiesa F; Di Leone A; Masetti R
    Eur Rev Med Pharmacol Sci; 2007; 11(5):283-9. PubMed ID: 18074936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
    J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    Henry NL; Hayes DF
    J Clin Oncol; 2007 Jun; 25(18):2501-3. PubMed ID: 17577024
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2 and response to paclitaxel in node-positive breast cancer.
    Mehta R
    N Engl J Med; 2008 Jan; 358(2):197-8; author reply 198. PubMed ID: 18193531
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neoadjuvant systemic chemotherapy for patients with operable breast cancer].
    Zhang B; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):161-5. PubMed ID: 17649628
    [No Abstract]   [Full Text] [Related]  

  • 20. Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?
    Tacca O; LeHeurteur M; Durando X; Mouret-Reynier MA; Abrial C; Thivat E; Bayet-Robert M; Penault-Llorca F; Chollet P
    Cancer Invest; 2009 Jan; 27(1):81-5. PubMed ID: 19191099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.